Financial Report: Hospira 3Q

Hospira 3Q

3Q Revenues: $949.3 million (-6%)

3Q Earnings: $71.4 million (-39%)

YTD Revenues: $2.9 billion (+4%)

YTD Earnings: $296.6 million (-4%)

Comments: Specialty Injectable Pharmaceuticals sales, including U.S. sales of Precedex, meropenem, vancomycin and heparin, help offset the temporary discontinuation of U.S. sales of oxaliplatin (due to a litigation settlement) and the decline in Medication Management Systems (-6% to $152.1 million). Specialty Injectables sales were $558.7 million in the quarter (-3%). Other Pharma revenues were $137.9 million (-12%). YTD Specialty Injectables sales were up 17% to $1.7 billion. YTD Medication Management Systems revenue was down 8% to $445.3 million.